Corcept Therapeutics Incorporated
Bear Case (25th pct.)
-93.3% vs price
Base Case (Median)
-92.2% vs price
Bull Case (75th pct.)
-92.0% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $9.40 | -92.0% | High (40%) |
| PE Comparable | $9.35 | -92.0% | Medium (25%) |
| Growth Trajectory DCF | $9.14 | -92.2% | Medium (20%) |
| Graham Number | $7.68 | -93.4% | Medium (40%) |
| EV/EBITDA | $6.58 | -94.4% | Medium (20%) |
| EV/FCF | $20.59 | -82.4% | Medium (20%) |
| Earnings Power Value | $8.04 | -93.1% | Medium (50%) |
Based on 7 out of 8 methods, CORT appears overvalued at the current price of $117.17. The base case fair value of $9.14 implies 92.2% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.